What a difference a week can make to a volatile stock. Following a significant swoon late last week, BioXcel Therapeutics (NASDAQ: BTAI) sharply reversed course in the subsequent frame. As of early Friday morning, according to data compiled by S&P Global Market Intelligence, its share price had rocketed more than 63% higher week to date. 

The monster sell-off occurred last Thursday, after BioXcel released the results from a phase 3 clinical trial of its BXCL501, a therapy that targets the agitation suffered by Alzheimer's disease patients. The results were encouraging, with the drug meeting its primary efficacy endpoint. It was also well tolerated, and produced no serious adverse events.

That wasn't the source of the concern, though. It soon came to light that an investigator at one of the trial's sites might not have been entirely honest in communicating about a significant side effect of the medication. Any alarm bell that relates to a biotech's clinical process is going to rattle the market.

Continue reading

Source Fool.com